HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Chandra Bhagat Pharma Ltd Stock Comparison

Alivus Life Sciences Ltd vs Chandra Bhagat Pharma Ltd Stock Comparison

Last Updated on: Jul 22, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1053 as of 22 Jul 12:19.
  • The P/E Ratio of Alivus Life Sciences Ltd changed from 13.4 on March 2022 to 20.2 on March 2024 . This represents a CAGR of 14.66% over 3 yearsThe P/E Ratio of Chandra Bhagat Pharma Ltd changed from 95.2 on March 2020 to 46.8 on March 2024 . This represents a CAGR of -13.24% over 5 years.
  • The Market Cap of Alivus Life Sciences Ltd changed from ₹ 5624 crore on March 2022 to ₹ 9499 crore on March 2024 . This represents a CAGR of 19.09% over 3 yearsThe Market Cap of Chandra Bhagat Pharma Ltd changed from ₹ 30.18 crore on March 2020 to ₹ 71.68 crore on March 2024 . This represents a CAGR of 18.89% over 5 years.
  • The revenue of Alivus Life Sciences Ltd for the Mar '25 is ₹ 659.63 crore as compare to the Dec '24 revenue of ₹ 652.3 crore. This represent the growth of 1.12% The revenue of Chandra Bhagat Pharma Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Alivus Life Sciences Ltd for the Mar '25 is ₹ 208.52 crore as compare to the Dec '24 ebitda of ₹ 200.76 crore. This represent the growth of 3.87% The ebitda of Chandra Bhagat Pharma Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 135.45 crore to ₹ 141.87 crore over 8 quarters. This represents a CAGR of 2.34% The net profit of Chandra Bhagat Pharma Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 58.56 % on March 2024 . This represents a CAGR of -1.60% over 3 yearsThe Dividend Payout of Chandra Bhagat Pharma Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
  • The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Chandra Bhagat Pharma Ltd

  • Chandra Bhagat Pharma Limited was incorporated as a Private Limited Company with the name 'Chandra Bhagat Pharma Private Limited' at Mumbai on March 10, 2003.
  • Consequent upon the conversion of the Company from Private Limited Company to Public Limited Company, the name of the Company was changed to 'Chandra Bhagat Pharma Limited' on March 20, 2019. The Company incorporated in March, 2003 by Mr. Hemant Bhagat and Late.
  • Shree Chandravadan Bhagat.
  • On April 1, 2003, the Company acquired the going concern business of M/s.
  • Chandra Bhagat Corporation, partnership firm along with all its assets and liabilities.

Alivus Life Sciences Ltd News Hub

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

News

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are amon...

Read more

21 Jan 2025 12:00

News

Glenmark Life Sciences renamed as Alivus Life Sciences

Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking a...

Read more

20 Jan 2025 10:18

Chandra Bhagat Pharma Ltd News Hub

News

Chandra Bhagat Pharma to conduct board meeting

Chandra Bhagat Pharma will hold a meeting of the Board of Directors of the Company on 29 M...

Read more

26 May 2025 18:43

News

Chandra Bhagat Pharma schedules board meeting

Chandra Bhagat Pharma will hold a meeting of the Board of Directors of the Company on 13 N...

Read more

11 Nov 2024 13:48

News

Chandra Bhagat Pharma to conduct AGM

Chandra Bhagat Pharma announced that the Annual General Meeting (AGM) of the company will ...

Read more

13 Sep 2024 11:49

News

Chandra Bhagat Pharma schedules AGM

Chandra Bhagat Pharma announced that the Annual General Meeting (AGM) of the company will ...

Read more

13 Sep 2024 11:41

News

Chandra Bhagat Pharma to declare Quarterly Result

Chandra Bhagat Pharma will hold a meeting of the Board of Directors of the Company on 30 M...

Read more

28 May 2024 15:32

News

Chandra Bhagat Pharma to declare Quarterly Result

Chandra Bhagat Pharma will hold a meeting of the Board of Directors of the Company on 9 No...

Read more

06 Nov 2023 20:02

SWOT Analysis Of Chandra Bhagat Pharma Ltd

Strength

1

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Chandra Bhagat Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and Chandra Bhagat Pharma Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Chandra Bhagat Pharma Ltd?

Market cap of Alivus Life Sciences Ltd is 12,950 Cr while Market cap of Chandra Bhagat Pharma Ltd is 43 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Chandra Bhagat Pharma Ltd?

The stock performance of Alivus Life Sciences Ltd and Chandra Bhagat Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Chandra Bhagat Pharma Ltd?

As of July 22, 2025, the Alivus Life Sciences Ltd stock price is INR ₹1056.05. On the other hand, Chandra Bhagat Pharma Ltd stock price is INR ₹57.95.

How do dividend payouts of Alivus Life Sciences Ltd and Chandra Bhagat Pharma Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Chandra Bhagat Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions